LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Allogene Therapeutics Inc

Cerrado

SectorSalud

1.2 5.26

Resumen

Variación precio

24h

Actual

Mínimo

1.18

Máximo

1.22

Métricas clave

By Trading Economics

Ingresos

8.8M

-51M

Margen de beneficio

272,450

Empleados

226

EBITDA

-335K

-57M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+696.61% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

30M

255M

Apertura anterior

-4.06

Cierre anterior

1.2

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Allogene Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 sept 2025, 23:56 UTC

Acciones populares

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 sept 2025, 22:01 UTC

Principales Movimientos del Mercado

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 sept 2025, 20:51 UTC

Adquisiciones, fusiones, absorciones

UPS Terminates Plan to Buy Estafeta

18 sept 2025, 20:31 UTC

Ganancias

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 sept 2025, 20:26 UTC

Ganancias

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 sept 2025, 23:43 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 sept 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 sept 2025, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

18 sept 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 sept 2025, 23:31 UTC

Charlas de Mercado

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 sept 2025, 22:03 UTC

Ganancias

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 sept 2025, 22:01 UTC

Ganancias

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 sept 2025, 21:56 UTC

Ganancias

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 sept 2025, 21:54 UTC

Ganancias

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 sept 2025, 21:48 UTC

Ganancias

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 sept 2025, 21:47 UTC

Ganancias

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 sept 2025, 21:17 UTC

Ganancias

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 sept 2025, 21:07 UTC

Ganancias

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sept 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

18 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 sept 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

18 sept 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

18 sept 2025, 20:22 UTC

Adquisiciones, fusiones, absorciones

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 sept 2025, 20:22 UTC

Adquisiciones, fusiones, absorciones

United Parcel Service Terminates Plan to Buy Estafeta

18 sept 2025, 20:20 UTC

Adquisiciones, fusiones, absorciones

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 sept 2025, 20:18 UTC

Ganancias

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 sept 2025, 20:18 UTC

Ganancias

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 sept 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

18 sept 2025, 20:07 UTC

Ganancias

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sept 2025, 20:03 UTC

Ganancias

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Comparación entre iguales

Cambio de precio

Allogene Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

696.61% repunte

Estimación a 12 meses

Media 9.4 USD  696.61%

Máximo 14 USD

Mínimo 7 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Allogene Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

7

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.18 / 1.69Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat